Oct 31, 2019
Pliant Therapeutics to Present Preclinical Data in Primary Sclerosing Cholangitis at The Liver Meeting 2019
Jul 09, 2019
Mirum Pharmaceuticals Initiates Phase 3 Clinical Trial for Pediatric Patients with Progressive Familial Intrahepatic Cholestasis
Apr 15, 2019
Mirum Pharmaceuticals Presents New Data Demonstrating Durable Improvements in Clinical Outcome Measures in Patients with PFIC2 and Alagille Syndrome Treated with Maralixibat
Mar 27, 2019
Mirum Pharmaceuticals to Present Phase 2 Clinical Results of Maralixibat in Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis at the International Liver Congress
Mar 21, 2019
Mirum Pharmaceuticals Appoints Chris Peetz as Chief Executive Officer
Nov 12, 2018
Data released at The Liver Meeting ® 2018 Shows MRCP+ is a Promising Non-Invasive Technology for Quantitative Evaluation of Hepatobiliary Diseases
Nov 07, 2018
Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases
Oct 03, 2018
HighTide Therapeutics Presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day
Sep 27, 2018
HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Primary Sclerosing Cholangitis
Apr 13, 2018
NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis
Feb 26, 2018
DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)
Oct 04, 2017
Biotranex LLC Granted Patent for Bile Salt Export Protein BSEPcyte(TM) Assay